Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Assets (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Current Assets for 11 consecutive years, with $49.4 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 27.67% to $49.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.4 million through Dec 2025, up 27.67% year-over-year, with the annual reading at $49.4 million for FY2025, 27.67% up from the prior year.
  • Current Assets hit $49.4 million in Q4 2025 for Seres Therapeutics, down from $51.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $358.8 million in Q3 2021 to a low of $38.7 million in Q4 2024.
  • Historically, Current Assets has averaged $172.6 million across 5 years, with a median of $185.1 million in 2022.
  • Biggest five-year swings in Current Assets: skyrocketed 212.77% in 2021 and later tumbled 77.95% in 2024.
  • Year by year, Current Assets stood at $303.6 million in 2021, then plummeted by 35.85% to $194.8 million in 2022, then dropped by 9.94% to $175.4 million in 2023, then crashed by 77.95% to $38.7 million in 2024, then rose by 27.67% to $49.4 million in 2025.
  • Business Quant data shows Current Assets for MCRB at $49.4 million in Q4 2025, $51.5 million in Q3 2025, and $48.7 million in Q2 2025.